Management of urinary incontinence in postmenopausal women: an EMAS clinical guide

30 September 2020 – A new clinical guide by the European Menopause and Andropause Society (EMAS) on the management of urinary incontinence in postmenopausal women is published in Maturitas. Urinary incontinence affects over 1 in 2 women aged over 60 years. The clinical guide provides evidence-based recommendations for the diagnosis and management of this common…

Management of urinary incontinence in postmenopausal women: an EMAS clinical guide

30 September 2020 – A new clinical guide by the European Menopause and Andropause Society (EMAS) on the management of urinary incontinence in postmenopausal women is published in Maturitas. Urinary incontinence affects over 1 in 2 women aged over 60 years. The clinical guide provides evidence-based recommendations for the diagnosis and management of this common…

EMAS position statement: menopause symptom management in women with dyslipidemias

Amsterdam, 4 April, 2020 – A new clinical guide by the European Menopause and Andropause Society (EMAS) published in the journal Maturitas provides an evidence-based approach to the menopausal symptom management in women with dyslipidemias (abnormal lipid levels), as well as to the management of dyslipidemias in postmenopausal women. Dyslipidemias are quite common disorders, constituting…

Management of depressive symptoms in peri- and post-menopausal women: EMAS Clinical Guide

Amsterdam, 7 November 2019 – A new position statement by the European Menopause and Andropause Society (EMAS) published in the journal Maturitas summarises the evidence about management of depression at the menopause. Globally, the total number of people with depression exceeds 300 million with a 70% greater incidence in women. The perimenopause is considered to…

EMAS clinical guide on menopause symptom management in women with dyslipidemias

Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile. Published in Maturitas EMAS  has  produced an evidence-based clinical guide evaluating the effects on the lipid profile both of menopausal hormone therapy and of non-estrogen-based treatments for menopausal symptoms. Click here to read more. Menopause…

Message from EMAS

The European Menopause and Andropause Society (EMAS) expresses it sympathy with those affected by the outbreak of COVID-19. We express our solidarity with the medical teams working around the clock to treat and contain the virus. COVID-19 has thankfully caused minimum disruption to the ongoing activities of EMAS. Our Congress is biennial (next edition 2021)…

EMAS and IGCS Position statement on managing the menopause after gynecological cancer

European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) Position statement on managing the menopause after gynecological cancer Worldwide, 1.3 million new gynecological cancer cases are diagnosed each year. Treatment can result in loss of ovarian function and, in women under the age of 45, early menopause.  This position statement provides an…